Dominiak P. Historic aspects in the identification of the I1 receptor and the pharmacology of imidazolines.
Cardiovasc Drugs Ther 1994;
8 Suppl 1:21-6. [PMID:
8068577 DOI:
10.1007/bf00877081]
[Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The central nervous system is involved in the control of arterial blood pressure. Stimulation of central alpha 2-adrenoceptors in the nucleus tractus solitarii (NTS) decreases sympathetic outflow, resulting in a fall in arterial blood pressure. One of the first antihypertensive substances with actions on the alpha 2-adrenoceptors of the NTS was alpha-methylnoradrenaline. Later on the imidazoline clonidine was developed for which numerous effects, mediated by alpha 2-adrenoceptors, in the CNS could be demonstrated. Since the centrally acting alpha 2-adrenoceptor agonists possess severe side effects, the development of more specific and selective centrally acting imidazolines resulted in the derivatives moxonidine and rilmenidine. The effects of the "second-generation imidazolines" could not be fully understood as alpha 2-adrenoceptor agonists. In the meantime, the rostral ventrolateral medulla (RVLM) has been identified as the site of action of the imidazolines and an I1-imidazoline binding site was characterized in this region. For the antihypertensive action of the imidazolines, agonism at the I1-imidazoline subtype seems to be responsible. In addition, an acid- and heat-stable endogenous substance, called clonidine displacing substance (CDS), was reported to bind at the putative I receptor. In 1992 a receptor protein for I receptors (70 kD) could be separated that is different from that of alpha 2-adrenoceptors. However, up to now we are still lacking the amino-acid sequence of the I receptor and its second messenger system.
Collapse